Showing results (1-10 of 96) with videos related to
Sort By:
Pageof 10
Health Economics|December 11, 2012
Optimal decision rules for HTA under uncertainty: a wider, dynamic perspectiveMartin Forster, Paolo PertileJournal of Health Economics|October 26, 2016
Late-stage pharmaceutical R&D and pricing policies under two-stage regulationSebastian Jobjörnsson, Martin Forster, Paolo Pertile, et al.Clinical Trials (London, England)|August 19, 2021
Cost-effective clinical trial design: Application of a Bayesian sequential model to the ProFHER pragmatic trialMartin Forster, Stephen Brealey, Stephen Chick, et al.International Journal of Health Care Finance and Economics|January 20, 2009
An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomographyPaolo PertileApplied Health Economics and Health Policy|December 3, 2019
Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and CompetitionRosella Levaggi, Paolo PertileHealth Economics|June 16, 2020
Which valued-based price when patients are heterogeneous?Rosella Levaggi, Paolo PertileJournal of Health Economics|September 16, 2021
R&D and market size: Who benefits from orphan drug legislation?Simona Gamba, Laura Magazzini, Paolo PertileHealth Economics|July 7, 2020
The impact of managed entry agreements on pharmaceutical pricesSimona Gamba, Paolo Pertile, Sabine VoglerHealth Policy (Amsterdam, Netherlands)|August 19, 2025
The 2023 European Commission proposal and the 2024 European Parliament proposal for the EU pharmaceutical legislation: policy content analysisSimona Gamba, Laura Magazzini, Paolo PertileHealth Policy (Amsterdam, Netherlands)|November 26, 2013
Two-part payments for the reimbursement of investments in health technologiesRosella Levaggi, Michele Moretto, Paolo PertilePageof 10